Back to search results

TRPC6 Study for Chemotherapy-Related Heart Problems in Breast Cancer

This study is looking at how a specific gene, TRPC6, might help predict and prevent heart problems in breast cancer patients receiving certain chemotherapy drugs like doxorubicin (an anthracycline) or trastuzumab. Some cancer treatments can affect the heart, and understanding these changes could lead to earlier help and new ways to protect your heart health long-term. Researchers will collect blood samples and review your medical records to study changes in your DNA. This will help them identify markers related to heart toxicity and potentially prevent these issues in patients undergoing chemotherapy. The study aims to understand the significance of TRPC6 gene variations. It is currently unclear if this study is recruiting new participants.

Study design
This is an observational study planning to enroll 200 participants. It is designed to look at information from patients without giving them a specific treatment.
What's involved
You would provide blood samples at the start of the study, and possibly more if you develop heart toxicity. Your medical records would also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, looking at TRPC6 gene sequencing, will be measured up to study completion, which could be up to four years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05507879

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~200 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:Biospecimen CollectionElectronic Medical Record

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Significance ofTRPC6 coding sequencing
Measured over Up to study completion, up to four years to completion.

Conditions

Breast Carcinoma
Cardiomyopathy
Congestive Heart Failure

Explore related trials

Breast Carcinoma

Where it's being run

2 sites across 1 states
Florida2

Study leadership

  • Nadine Norton, Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Any breast cancer patient initiating doxorubicin/other anthracycline and patients receiving trastuzumab without doxorubicin/anthracycline in the neoadjuvant/adjuvant setting
An understanding of the protocol and its requirements, risks, and discomforts
The ability and willingness to sign an informed consent
Diagnosed with therapy related cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment OR completed chemotherapy with no cardiotoxicity at least two years post treatment OR patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include doxorubicin chemotherapy, or trastuzumab.
Healthy, non-pregnant, adult subjects who weigh at least 110 pounds

Exclusion

Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Anemia with hemoglobin less than 8
Patients not willing to undergo a blood draw
Patients with stage IV or distant metastatic breast cancer

What this trial measures

  • Significance ofTRPC6 coding sequencingUp to study completion, up to four years to completion.

    Will compare the prevalence of rare missense variants in our cases against the null hypothesis to assess the significance of TRPC6 coding sequencing data in patients with dox-induced heart failure (HF). Will use an exploratory analysis to estimate the prevalence, 95% confidence intervals and p-values depending on the number of patients with rare variants in the data set and due to the rarity (i.e. high degree of conservation in the TRPC6 coding sequence).Other methods include biospecimen collection and the TRPC6 coding sequence. Data collected will be stored in a database and studied by the PI.